Novo Nordisk has front-loaded DKK 1 billion of restructuring costs into the third quarter, positioning those savings to flow through in Q4 results. With expectations tempered by recent guidance cuts, the company’s ability to deliver a year-end beat on low consensus forecasts hinges on realizing these savings. Investors should note that operational efficiencies from the restructuring programme will also support margin improvement, particularly as SG&A expense growth moderates into 2026.

In early January 2026, Novo Nordisk launched its FDA-approved Wegovy oral tablet, marking the first oral GLP-1 agonist approved for chronic weight management. The pill recorded more than 18,000 prescriptions in its debut week, signaling robust demand from both primary care physicians and specialist clinics. By converting a segment of the existing injectable patient base and attracting new users averse to injections, the launch effectively increases the U.S. addressable population to approximately 85 million adults struggling with overweight or obesity.

To support accelerating demand for both Ozempic and Wegovy, Novo Nordisk’s partnership with Catalent will integrate a fill-finish site in the U.S., doubling domestic manufacturing capacity by mid-2026. This expansion aims to mitigate prior bottlenecks that led to periodic supply constraints and elevated logistics costs. Enhanced throughput and shorter lead times are expected to drive gross margin expansion, while also providing a hedge against competitive pressures from rivals and telehealth entrants.